New & Noteworthy

September 2018

Sublingual Film to Treat Opioid Dependence

Dr. Reddy's Laboratories Inc

Dr. Reddy’s Laboratories have received final approval from the US FDA and is launching
buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of suboxone (buprenorphine and naloxone) sublingual film. In treating adults with opioid dependence/addiction, buprenorphine helps suppress withdrawal symptoms caused by discontinuation of opioid drug use, and naloxone reverses and blocks the effect of opioids. This combination of medications is used as part of a complete treatment program including prescription monitoring, counseling, and psychosocial support.

Request More Information

Current Issue